-
Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia
Monday, February 3, 2020 - 12:47pm | 589Read More...Aimmune Therapeutics Inc (NASDAQ: AIMT) announced late Friday that it received FDA approval for Palforzia, its oral immunotherapy to treat peanut allergy. The Aimmune Analysts Baird analyst Brian Skorney maintained an Outperform rating and $64 price target for Aimmune shares. RBC Capital...
-
BioMarin's Upcoming Catalysts Named By Credit Suisse
Monday, January 23, 2017 - 10:57am | 270Read More...BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares have historically outperformed during product launches, and Credit Suisse’s Kennen MacKay expects the Brineura launch in Q2:17 and upcoming launches of Vosoritide and PEG-PAL to drive earnings as well as investor interest. MacKay initiated...
-
Here's What To Expect Following Trump's Drug Pricing 'Robbery' Comments
Tuesday, January 17, 2017 - 12:33pm | 345Read More...Perhaps the only thing that traders can know for certain about President-elect Donald Trump’s policy decisions is that they should always expect the unexpected. Biotech investors thought they had scored a major victory in November when Trump defeated Hillary Clinton. Clinton had made...
-
2 Reasons Seattle Genetics' Clinical Holds Were A Surprise
Wednesday, December 28, 2016 - 11:16am | 247Read More...On Tuesday, Seattle Genetics, Inc. (NASDAQ: SGEN) announced that the FDA had imposed several clinical holds upon the Phase I trials for SGN-CD33A due to cases of hepatic veno-occlusive disease. Credit Suisse’s Kennen MacKay maintains a Neutral rating on the company, while lowering the price...
-
Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone
Monday, November 14, 2016 - 5:37pm | 352Read More...Credit Suisse said in the aftermath a huge selloff in Puma Biotechnology Inc (NYSE: PBYI) that the pullback is overdone, although diarrhea remains a concern. Analyst Kennen MacKay noted that the abstracts for the SABCS conference showed that the rates of gr3 diarrhea rose to 27 percent...
-
Clovis Upgraded At Credit Suisse Following Acquisition Rumor
Wednesday, September 21, 2016 - 7:38am | 333Read More...Clovis Oncology Inc (NASDAQ: CLVS) is a potential takeout target for a global pharma company, Credit Suisse’s Kennen MacKay said in a report. He upgraded the rating on the company from Neutral to Outperform, while raising the price target from $19 to $41. Following the FDA’s...
-
Medivation Execs Making A Strong Case For Independent Growth Vs. Sale, Credit Suisse Says
Friday, May 6, 2016 - 8:28am | 274Read More...Medivation Inc (NASDAQ: MDVN) reported its 1Q16 US/EU Xtandi sales and non-GAAP EPS short of expectations. Credit Suisse’s Kennen MacKay maintained an Outperform rating for the company, with a price target of $63. Medivation posted Q1 US Xtandi sales at $307.6M and EU sales at $240M. Non-...
-
Credit Suisse: Medivation Could Be Worth $54 To $75 In Takeout, But Management Won't Sell
Thursday, March 31, 2016 - 11:27am | 247Read More...After Wednesday's market close, news reports suggested that Medivation Inc (NASDAQ: MDVN) had hired bankers to defend the company against acquisition. Credit Suisse’s Kennen MacKay maintained an Outperform rating on the company, while raising the price target from $48 to $49....
-
Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks
Thursday, January 21, 2016 - 1:16pm | 318Read More...In a new report, Credit Suisse analyst Kennen MacKay discussed the firm’s top biotech stock picks. According to MacKay, it’s important for investors to remain selective, as the biotech sector undergoes a market correction. Credit Suisse focused on four themes when identifying top...
-
The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron
Thursday, January 21, 2016 - 8:35am | 286Read More...Acceleron Pharma Inc (NASDAQ: XLRN) shares have plunged 23 percent since December 21. Credit Suisse’s Kennen MacKay initiated coverage of the company with an Outperform rating and a price target of $50. The Street is less bullish about luspatercept due to competition from gene...
